Avinger (AVGR) Misses Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Avinger (AVGR) Misses Q3 EPS by 21c
November 5, 2015 4:09 PM EST
Received FDA Clearance for Pantheris
Accelerated Expansion of Installed Base of Lumivascular Platform
REDWOOD CITY, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported results for the third quarter ended September 30, 2015.
Recent Highlights
Received 510(k) clearance from the United States Food and Drug Administration (FDA) to commence U.S. commercialization of Pantheris, the first-ever image-guided atherectomy device using...
More
November 3, 2015 4:05 PM EST
REDWOOD CITY, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced the Company will be participating in two upcoming investor conferences.
Avinger's management is scheduled to present at the Stephens Fall Investment Conference in New York City, NY on... More
